eCORE
- Chronic, Prevalent Diseases & Aging
- Personalized Medicine, Innovative Diagnostics, Molecular Imaging & Digital Health
Team
Group Leader
Rafael Simó Canonge
Principal Investigator (PI)
Cristina Hernández, Andreea Ciudin, Olga-Simó Servat, David M Selva, Josep A. Villena
Researchers
Rosa Burgos, Betina Biagetti, Enzamaría Fidilio, Ángel M. Ortiz, Carles Zafon, Anna Casteràs, Alejandra Planas, Judit Amigó, Fiorella Palmas, Alba Zabalegui, Vanesa Flores, Julia García, Patricia Bogdanov, Marta Garcia-Ramírez, Maria Llorián-Salvador, Julia Hernández, Anna Alvarez-Guaita
PhD Students
Hugo Ramos, Anna Deàs-Just, Laura Hidalgo
Lab Technicians
Lorena Ramos, Rosario Pardo, David Sabater, Jordi Huerta
Nursing and Technical Staff
Marc Rivas, Mercè Abad, Mónica Sánchez, Marcos do Santos, Fátima Cuadra, Marta Comas
Selected Publications
Llorián-Salvador M, Pérez-Martínez D, Tang M, Duarri A, García-Ramirez M, Deàs-Just A, Álvarez-Guaita A, Ramos-Pérez L, Bogdanov P, Gomez-Sanchez JA, Stitt AW, Hernández C, de la Fuente AG, Simó R.
Regulatory T cell expansion prevents retinal degeneration in type 2 diabetes.
J Neuroinflammation. 2024 Dec 23;21(1):328.
DOI: 10.1186/s12974-024-03323-0
IF: 9.30
Ramos H, Augustine J, Karan BM, Hernández C, Stitt AW, Curtis TM, Simó R.
Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2+/- rat model.
J Neuroinflammation. 2024 Nov 30;21(1):312.
DOI: 10.1186/s12974-024-03283-5
IF: 9.30
Li J, Guan Z, Wang J, Cheung CY, Zheng Y, Lim LL, Lim CC, Ruamviboonsuk P, Raman R, Corsino L, Echouffo-Tcheugui JB, Luk AOY, Chen LJ, Sun X, Hamzah H, Wu Q, Wang X, Liu R, Wang YX, Chen T, Zhang X, Yang X, Yin J, Wan J, Du W, Quek TC, Goh JHL, Yang D, Hu X, Nguyen TX, Szeto SKH, Chotcomwongse P, Malek R, Normatova N, Ibragimova N, Srinivasan R, Zhong P, Huang W, Deng C, Ruan L, Zhang C, Zhang C, Zhou Y, Wu C, Dai R, Koh SWC, Abdullah A, Hee NKY, Tan HC, Liew ZH, Tien CS, Kao SL, Lim AYL, Mok SF, Sun L, Gu J, Wu L, Li T, Cheng D, Wang Z, Qin Y, Dai L, Meng Z, Shu J, Lu Y, Jiang N, Hu T, Huang S, Huang G, Yu S, Liu D, Ma W, Guo M, Guan X, Yang X, Bascaran C, Cleland CR, Bao Y, Ekinci EI, Jenkins A, Chan JCN, Bee YM, Sivaprasad S, Shaw JE, Simó R, Keane PA, Cheng CY, Tan GSW, Jia W, Tham YC, Li H, Sheng B, Wong TY.
Integrated image-based deep learning and language models for primary diabetes care.
Nat Med. 2024 Oct;30(10):2886-2896.
DOI: 10.1038/s41591-024-03139-8
IF: 58.70
Ortiz-Zúñiga A, Amigó J, Sánchez M, Abad M, Simó R, Hernández C, Simó-Servat O.
Impact in real-world of intermittent-scanned continuous glucose monitoring with alarms on hypoglycemia and its recognition in type 1 diabetes.
Diabetes Res Clin Pract. 2024 Aug;214:111786.
DOI: 10.1016/j.diabres.2024.111786
IF: 6.10
Ciudin A, Hernández C, Simó-Servat O, Simó R
The usefulness of the retina for identifying people with type 2 diabetes with prodromal stages of dementia.
Neurosci Biobehav Rev. 2024 Apr;159:105592
DOI: 10.1016/j.neubiorev.2024.105592
IF: 7.60
Selected Projects
Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia (RECOGNISED
Principal Investigator: Rafael Simó
Agency: EC-Horizon2020. Grant Agreement 847749
Funding: 5,998,273 €
Period: 2019-2024
Study of safety and effectiveness of topical administration (eye drops) of sitagliptin for treating early stages of diabetic retinopathy (EyeSit@)
Principal Investigator: Rafael Simó
Agency: Instituto de Salud Carlos III. Proyectos de Investigación Clínica Independiente. ICI20/00129
Funding: 534,000 €
Period: 2021-2026
Hemopexin: un nuevo factor patogénico en las complicaciones microvasculares de la diabetes
Principal Investigator: Cristina Hernández
Agency: Instituto de Salud Carlos III. PI22/01670
Funding: 164,000 €
Period: 2023-2025
Desarrollo de EDL6D, un péptido mimético de SHBG para el tratamiento de la enfermedad del hígado graso no alcohólico (NAFLD) y la esteatohepatitis no alcohólica (NASH)
Principal Investigator: David M Selva
Agency: Ministerio Ciencia e Innovación. CPP2022-009831
Funding: 843,224 €
Period: 2023-2026
Desarrollo clínico de RetSit@, un fármaco neuroprotector first-in-class para tratar los Estadíos Tempranos de la Retinopatía Diabética.
Principal Investigator: Rafael Simó
Agency: CPP2023-010602 (Proyectos de Colaboración Público Privada) Ministerio de Ciencia, Innovación y Universidades. Agencia Estatal de Investigación
Funding: 1,4M €
Period: 2024-2027
Patents
Inhibidores de la dipeptidil peptidasa-4 para su uso en el tratamiento tópico ocular de enfermedades neurodegenerativas de la retina, en particular en estadios tempranos de retinopatía diabética y otras enfermedades retinianas en las que la neurodegeneración desempeña un papel esencial.
Priority Number: PCT/EP2017/060234
Priority Date: 29/04/2016
Applicants: VHIR (100%)
Péptido derivado de SOCS1 para su uso en complicaciones crónicas de la diabetes
Priority Number: P201430796
Priority Date: 28/05/2014
Applicants: VHIR (49%) /Fundación Jiménez Díaz (26%) / Universidad Autónoma de Madrid (25%)
Sex-hormone-binding globulin for use as medicament
Priority Number: EP13382202.3
Priority Date: 30/05/2013
Applicants: VHIR (100%)
Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
Priority Number: PCT/EP2014/053787
Priority Date: 01/03/2013
Applicants: VHIR (100%)
Antibodies or fragments thereof for use in the treatment of ocular diseases
Priority Number: PCT/EP2013/058836
Priority Date: 30/04/2012
Applicants: VHIR (100%)
